Codexis Named Finalist for CPhI Pharma Award for Best Innovation in Process
CPhI Worldwide 2013
REDWOOD CITY, Calif. -- October 2, 2013
Codexis, Inc. (NASDAQ: CDXS), a developer of engineered enzymes for
pharmaceutical, biofuel and chemical production, today announced that it has
been named as a finalist for the CPhI Pharma Awards in the “Best Innovation in
Process Development” category. The award ceremony will take place on October
22, 2013 in Frankfurt, Germany as part of the annual CPhI Worldwide
exhibition, which is expected to attract around 30,000 visitors from the
Codexis has been selected as a finalist following its development of the first
industrially-viable biocatalysts for sulfide oxidation and Baeyer-Villiger
type monooxygenations (BVMO enzymes). These optimized enzymes can be used for
improved methods to manufacture chiral sulfoxides, which are important
molecules for the pharmaceutical industry. Codexis has used these new enzymes
to develop innovative biocatalytic processes for the production of
esomeprazole and armodafinil that overcome the shortcomings of traditional
manufacturing, including the ability to provide consistently high
enantiometric purity and minimal sulfone impurity. The enzyme and API
manufacturing processes are currently being scaled up for commercial supply.
“We are very pleased to be named a finalist for the CPhI 2013 Pharma Awards,”
said John Nicols, President and CEO of Codexis. “Biocatalysis can offer
faster, more efficient, cost-effective and greener manufacturing routes for
many pharmaceutical products and we look forward to presenting our sulfide
oxidation and BVMO enzyme technologies to the final judging panel at CPhI in
Frankfurt during this well-respected industry event.”
Codexis’ BVMO enzymes are now commercially available as a screening kit that
process chemists can use to explore new biocatalytic oxidation processes,
which can then be readily scaled up as needed.
Codexis will be exhibiting in Hall 3.1, Booth A53 at the CPhI Worldwide
About Codexis, Inc.
Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and implementation of
biocatalytic solutions to meet customer needs for rapid, cost-effective and
sustainable process development – from research to manufacturing. For more
information, see www.codexis.com.
Paul Cox, 212-362-1200
Jemma Connor, +44 161 359 3255
Press spacebar to pause and continue. Press esc to stop.